Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

TP53 aberrant Mantle Cell Lymphoma treated with first-line systemic therapy: A real-world analysis of outcomes in 120 patients treated in the United Kingdom

Blood (2025) 146 (Supplement 1): 1827.

https://doi.org/10.1182/blood-2025-1827

Published: 2025

Journal Articles

Initial results of a CRUK phase I/II, first in human trial of the CAR t-cell engager protein aleta-001 in patients who have received anti-CD19 CAR t-cell therapy for the treatment of b-cell malignancies

Blood (2025) 146 (Supplement 1): 925.

https://doi.org/10.1182/blood-2025-925

Published: 2025

Journal Articles

Checkpoint inhibitors improve progression free survival after autologous transplant despite poorer pre-transplant response

Jack Taylor-Stuart, Mark Ethell, Mike Potter, Sandra Easdale, Chloe Anthias, Caroline Furness, David Cunningham, Ian Chau, Dima El-Sharkawi, Sunil Iyengar, Emma Nicholson

Blood (2025) 146 (Supplement 1): 7134.

https://doi.org/10.1182/blood-2025-7134

Published: 2025

Journal Articles

Multiparametric integration improves diagnostic categorisation of mature, non-CLL B-cell leukemias including atypical CLL - results from the prospective enable-NGS study

Blood (2025) 146 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2025-1753

Published: 2025

Journal Articles

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Blood (2025) 146 (Supplement 1): 884.

https://doi.org/10.1182/blood-2025-884

Published: 2025

Journal Articles

Relapsed/Refractory Hodgkin lymphoma after first-line escalated beacopdac: Adverse outcomes are overcome by use of second-line targeted therapy - an international real-world analysis

Blood (2025) 146 (Supplement 1): 3623.

https://doi.org/10.1182/blood-2025-3623

Published: 2025

Journal Articles

Extreme thrombocytosis in patients with underlying malignancy; Management, complications and outcomes.

Laura McDonald, Heba Hasan, Lorelyn Donato, Lillie Anne Wylde, Rifa Cardoso, Kevin Boyd, Rita Peralta, Sunil Iyengar, Dima El-Sharkawi

Blood (2025) 146 (Supplement 1): 6591.

https://doi.org/10.1182/blood-2025-6591

Published: 2025

Journal Articles

Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Blood (2024) 144 (Supplement 1): 3100.

https://doi.org/10.1182/blood-2024-203781

Published: 2024

Journal Articles

Role of Bruton Tyrosine Kinase Inhibitors (BTKi) in Relapsed Refractory (r/r) Hairy Cell Leukaemia Patients: A Single-Centre Real-World Data Set from the Royal Marsden Hospital

Francesca Emily Sillito, Lucy Pickard, Ravindi Miriam, Paras Shah, Sunil Iyengar, Dima El-Sharkawi

Blood (2024) 144 (Supplement 1): 6311.

https://doi.org/10.1182/blood-2024-206992

Published: 2024

Journal Articles

Excellent Outcomes with Brentuximab-Nivolumab for Relapsed/ Refractory Primary Mediastinal B-Cell Lymphoma in the Real-World Setting

Lucy Pickard, Li Yuan Chan, Su Li, Michael Potter, Emma Nicholson, Ian Chau, David Cunningham, Juanah Addada, Emily Chernucha, Sunil Iyengar, Dima El-Sharkawi

Blood (2024) 144 (Supplement 1): 3085.

https://doi.org/10.1182/blood-2024-204653

Published: 2024

Journal Articles

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

Blood (2024) 143 (2): 152–165.

https://doi.org/10.1182/blood.2023021348

Published: 2024

Includes: Supplemental data

Journal Articles

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 174.

https://doi.org/10.1182/blood-2023-189835

Published: 2023

Journal Articles

Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital

Farheen Mir, Anna Robinson, Mark Edward Ethell, Michael Potter, Emma Nicholson, Chloe Anthias, Sandra Easdale, Carlos Gonzalez-Arias, Amit Sud, Claire E. Dearden, Ian Chau, David Cunningham, Dima El-Sharkawi, Bhupinder Sharma, Sunil Iyengar

Blood (2022) 140 (Supplement 1): 9366–9367.

https://doi.org/10.1182/blood-2022-166198

Published: 2022

Journal Articles

Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Blood (2022) 140 (Supplement 1): 1761–1764.

https://doi.org/10.1182/blood-2022-166543

Published: 2022

Journal Articles

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Blood (2022) 140 (Supplement 1): 9470–9472.

https://doi.org/10.1182/blood-2022-159586

Published: 2022

Journal Articles

Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Andrea Visentin, Lydia Scarfò, Thomas Chatzikonstantinou, Anargyros Kapetanakis, Christos Demosthenous, Georgios Karakatsoulis, Martin Andres, Darko Antic, David Allsup, Mónica Baile, Dominique Bron, Antonella Capasso, Mark Catherwood, Rosa Collado, Raul Cordoba, Carolina Cuéllar-García, Julio Delgado, Maria Dimou, Michael Doubek, Lorenzo De Paoli, Maria Rosaria De Paolis, Giovanni Del Poeta, Maria Efstathopoulou, El-Ashwah Shimaa, Alicia Enrico, Lucia Farina, Angela Ferrari, Myriam Foglietta, Moritz Furstenau, Jose A. Garcia-Marco, Massimo Gentile, Eva Gimeno, Gomes da Silva Maria, Odit Gutwein, Yervand Hakobyan, Yair Herishanu, jose Angel Hernandez, Tobias Herold, Sunil Iyengar, Gilad Itchaki, Ozren Jaksic, Ann Janssens, Olga Kalashnikova, Elzbieta Kalicinska, Arnon P. Kater, Sabina Kersting, Jorge Labrador, Deepesh Lad, Luca Laurenti, Mark-David Levin, Enrico Lista, Lara Malerba, Roberto Marasca, Monia Marchetti, Juan Marquet Palomanes, Mattias Mattsson, Francesca Romana Mauro, Carlota Mayor-Bastida, Marta Morawska, Marina Motta, Talha Munir, Roberta Murru, Ivana Milosevic, Fatima Miras Calvo, Carsten Utoft Niemann, Jacopo Olivieri, Lorella Orsucci, Maria Papaioannou, Miguel Arturo Pavlovsky, Inga S. Piskunova, Barbara Pocali, Viola Maria Popov, Francesca Maria Quaglia, Giulia Quaresmini, Doreen te Raa, Gianluigi Reda, Gian Matteo Rigolin, Rosa Ruchlemer, Amit Shrestha, Martin Šimkovič, Martin Špaček, Paolo Sportoletti, Oana Stanca Ciocan, Tamar Tadmor, Elisabeth Vandenberghe, Marzia Varettoni, Candida Vitale, Ellen Van Der Spek, Michel Van Gelder, Ewa Wasik-Szczepanek, Lucrecia Yáñez, Mohamed A Yassin, Marta Coscia, Barbara Eichhorst, Alessandro Rambaldi, Niki Stavroyianni, Livio Trentin, Kostas Stamatopoulos, Paolo Ghia

Blood (2022) 140 (Supplement 1): 2333–2337.

https://doi.org/10.1182/blood-2022-163259

Published: 2022

Journal Articles

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Blood (2022) 140 (Supplement 1): 3673–3677.

https://doi.org/10.1182/blood-2022-157583

Published: 2022

Journal Articles

Does R-IPI Remain Predictive of Relapse Risk for Patients with DLBCL Achieving a Complete Remission with Frontline Therapy: Landmark Analysis of Two Large Prospective Clinical Trials

Dima El-Sharkawi, Tasneem Elnafie, Sarah Thompson, Louise Stanton, Nicholas Counsell, Amit Sud, Ian Chau, Bhupinder Sharma, Peter Johnson, David C. Linch, Sunil Iyengar, Andrew Davies, David Cunningham

Blood (2022) 140 (Supplement 1): 7908–7909.

https://doi.org/10.1182/blood-2022-167852

Published: 2022

Journal Articles

Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom

Blood (2022) 140 (Supplement 1): 7519–7521.

https://doi.org/10.1182/blood-2022-165031

Published: 2022

Journal Articles

Avenue - Avelumab in the Frontline Treatment of Advanced Classic Hodgkin Lymphoma - a Window Study

Stephen Booth, Eliza Hawkes, Amy A Kirkwood, Sally F Barrington, Patrick G. Medd, Pamela McKay, Ruth Pettengell, Sunil Iyengar, Fiona Miall, John Radford, Cathy Burton, Amit Sud, Nimish Shah, Andrew M Scott, Arzhang Ardavan, Michael Northend, Laura Clifton-Hadley, Richard Jenner, Graham P. Collins

Blood (2021) 138 (Supplement 1): 2470.

https://doi.org/10.1182/blood-2021-145189

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

TP53 aberrant Mantle Cell Lymphoma treated with first-line systemic therapy: A real-world analysis of outcomes in 120 patients treated in the United Kingdom

Initial results of a CRUK phase I/II, first in human trial of the CAR t-cell engager protein aleta-001 in patients who have received anti-CD19 CAR t-cell therapy for the treatment of b-cell malignancies

Checkpoint inhibitors improve progression free survival after autologous transplant despite poorer pre-transplant response

Multiparametric integration improves diagnostic categorisation of mature, non-CLL B-cell leukemias including atypical CLL - results from the prospective enable-NGS study

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Relapsed/Refractory Hodgkin lymphoma after first-line escalated beacopdac: Adverse outcomes are overcome by use of second-line targeted therapy - an international real-world analysis

Extreme thrombocytosis in patients with underlying malignancy; Management, complications and outcomes.

Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Role of Bruton Tyrosine Kinase Inhibitors (BTKi) in Relapsed Refractory (r/r) Hairy Cell Leukaemia Patients: A Single-Centre Real-World Data Set from the Royal Marsden Hospital

Excellent Outcomes with Brentuximab-Nivolumab for Relapsed/ Refractory Primary Mediastinal B-Cell Lymphoma in the Real-World Setting

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital

Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Does R-IPI Remain Predictive of Relapse Risk for Patients with DLBCL Achieving a Complete Remission with Frontline Therapy: Landmark Analysis of Two Large Prospective Clinical Trials

Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom

Avenue - Avelumab in the Frontline Treatment of Advanced Classic Hodgkin Lymphoma - a Window Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only